PTK7 and acute lymphoblastic leukemia: In addition to their ability to differentiate PTK7+ T-cell ALL cells from healthy cells, the Sgc8 aptamers can also be engineered as targeting ligands, thereby enabling the selective delivery of therapeutic cargos to target cells.